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Raluca cosgarea1,2,3*, S. Eick4, S. Jepsen1, N. B. Arweiler3, R. Juncar5, R. Tristiu2, G. E. Salvi4, 
C. Heumann6 & A. Sculean4
Nonsurgical periodontal therapy with adjunctive use of systemic antimicrobials (for 7–14 days) 
showed improved clinical, microbiological and immunological results over the mechanical protocol 
alone. Considering the increasing risk for antimicrobial resistance with longer antibiotic regimes, 
it is important to establish the optimal antibiotic protocol with a maximum antimicrobial benefit 
and minimum risk for adverse effects. The aim of the study was to evaluate the microbiological 
and inflammatory outcomes 12-months after a 3-/7-day systemic antibiotic protocol [amoxicillin 
(AMX) + metronidazole (MET)] adjunctive to subgingival debridement in severe periodontitis 
compared to mechanical treatment alone. From the initially treated 102 patients, 75 subjects 
(Placebo group: n = 26; 3-day AMX + MET group: n = 24; 7-day AMX + MET group: n = 25) completed 
the 12-month examination. Clinical parameters, eight periodontal pathogens and inflammatory 
markers were determined at baseline and 3-, 6-, 12-months after therapy using real-time PCR and 
ELISA respectively. After 6 months, several periodontopathogens were significantly more reduced 
in the two antibiotic groups compared to placebo (p < 0.05). After 1 year, both antibiotic protocols 
showed significant reductions and detection of the keystone pathogen P. gingivalis compared to 
placebo. Antibiotic protocols, smoking, disease severity, baseline-BOP, -CAL and -IL-1β, as well as 
detection of T. denticola at 12-months significantly influenced the residual number of deep sites. The 
present data indicate that the systemic use of both short and longer antibiotic protocols (AMX + MET) 
adjunctive to nonsurgical periodontal therapy lead to higher microbiological improvements compared 
to subgingival debridement alone. The two investigated antibiotic protocols led to comparable 
microbiological and inflammatory results.
Since periodontitis is a biofilm-induced inflammatory multifactorial chronic disease, periodontal treatment 
aims at reducing the supra- and subgingival biofilm by institution of an adequate oral hygiene and meticulous 
open
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debridement of the roots (i.e. subgingival debridement-SD) in order to resolve tissue inflammation and arrest 
disease  progression1. Despite the fact that SD has been shown to be successful in reducing periodontal pathogens 
in the subgingival  area2,3, evidence exists that major periodontal pathogens like Aggregatibacter actinomycetem-
comitans or Porphyromonas gingivalis may not be completely eliminated by mechanical debridement alone and 
their persistence has been associated with further tissue  breakdown4–6. Vice versa, the absence of certain peri-
odontal pathogens has been associated with lower risk for further attachment-loss7–9. Consequently, systemic 
antimicrobials had been introduced in the late 80ies as adjuncts to mechanical debridement to reinforce SD and 
sustain the host-defence system by reaching the pathogens not always accessible for mechanical instruments 
(i.e. root-concavities, furcations) or in other mouth areas (i.e. pharynx, tongue)10.
In this sense, several antimicrobials and various combinations thereof had been implemented in the non-
surgical periodontal treatment showing improved clinical, microbiological and immunological results over the 
mechanical protocol  alone11–15. The use of a combination of amoxicillin (AMX) and metronidazole (MET) 
dominates the literature in this  topic14–16, indicating a synergistic efficiency against gram-negative anaerobes in 
 particular17–21. Statistically significantly better clinical outcomes regarding probing pocket depth (PD) reduction 
and clinical attachment level (CAL)  gain11,13,22–33 as well as significant reduction of periodontal pathogens and 
of inflammatory cytokines were observed for the systemic use of AMX + MET adjunctive to SD compared to 
mechanical treatment  alone22–32,34,35. However, it is important to emphasize that for initially shallow (PD < 4 mm) 
and moderate (PD 4–5 mm) sites in patients with chronic periodontitis, the adjunctive use of AMX + MET has 
been shown to have only minimal additional clinical benefits (PD reduction and CAL gain)13,36. On the other 
hand, initially deep sites (PD > 6 mm) have demonstrated substantial additional clinical improvements (i.e. 
0.74 mm PD reduction and 0.61 mm CAL gain after 12 months)13, thus decreasing significantly the need for sub-
sequent surgical periodontal  therapy22,25,30,37. Moreover, it has been shown that patients taking the antimicrobials 
at the initial phase of the periodontal treatment, exhibited significantly greater clinical improvements in initially 
deep sites compared to those taking the antimicrobials after healing or at the second  stage25,37.
Despite the abundance of studies on AMX + MET in non-surgical periodontal therapy, there seems to be 
no consensus regarding the optimal dosage and duration of the medication: doses of each of the antimicrobials 
range from 200 to 500 mg for durations of 3–14  days20–30,32,33,38–41. In the light of an increasing risk for antimicro-
bial resistance with longer antibiotic regimes, it is important to establish the optimal antibiotic protocol with a 
maximum antimicrobial benefit and minimum risk for adverse events (i.e. antibiotic resistance, hypersensitivity, 
renal/liver toxicity, e.t.c). This has to consider the pharmacological principle that antimicrobials should be taken 
in a minimum bactericidal concentration for a minimum  duration42 and is in concordance with the current 
worldwide concern regarding the critical levels of antibiotic resistance as a result of the indiscriminative use of 
 antimicrobials12,43,44. Since the discovery of antimicrobials in the 1940s, the abundance of antibiotic-resistant 
genes has significantly  increased45. Evidence also indicates that oral microbiota represent a reservoir for transfer-
able antimicrobial resistant  genes46–49 having the potential to transfer antimicrobial resistance in patients under-
going antibiotic therapy as  well50. Thus, it seems mandatory, that not only in various field of general medicine 
the antibiotic prescription and protocol should be reanalysed and clearly  defined51, but also in dentistry and 
especially in periodontal therapy there is an urgent need to establish the optimal antibiotic protocol and the class 
of patients that may really benefit from it.
Studies evaluating the clinical, microbiological and immunological efficacy of a short-term administration of 
AMX + MET compared to the standard protocol (e.g. use for at least 7 days) in non-surgical periodontal therapy 
are scarce. Lately, we have evaluated the clinical outcomes at 6 and 12 months of a 3-day regimen of AMX + MET 
adjunctive to SD in severe chronic periodontitis showing that both antibiotic protocols (3 and 7 days) led to 
statistically significant better clinical improvements compared to SD  alone33,41. The aim of the present analysis, 
was therefore to evaluate the microbiological and inflammatory biomarkers outcomes following non-surgical 
periodontal therapy in conjunction with systemic administration of AMX + MET for 3 or 7 days in patients with 
severe chronic periodontitis (stage III–IV, grade B periodontitis). The present article represents the microbiologi-
cal and inflammatory analyses of a previous RCT 33,41.
Results
Patients. Hundred two subjects (mean age 43.37 ± 9.85, 65 female, 35 smokers, n = 34/group) were enrolled 
in the study and 27 patients dropped-out at the 12-month evaluation. Reasons for exclusion from the final 
analysis were antibiotic intake for other medical reasons, non-compliance with the appointments schedule and 
moved out of town. No statistically significant differences (p > 0.05) between the groups were detectable at base-
line (i.e. for gender distribution, smoking status, clinical parameters: PD, CAL, BOP, FMPS, number of deep sites 
with PD ≥ 6 mm, e.t.c.) (Table 1 in Cosgarea et al.)33. Excellent patient compliance with the pills intake and only 
minor adverse events were registered in all three treatment  groups33. The main outcomes at 12 months indicated 
statistically significantly better clinical improvements (i.e. PD-reduction, CAL-gain) for the 7-day antimicrobial-
protocol as compared to placebo, while statistically significantly fewer residual deep sites (PD ≥ 6 mm) were 
present in the 3-day Antimicrobial-group as compared to  placebo41. Additionally, statistically significantly more 
patients reached a periodontal status with low risk for disease progression (≤ 4 sites with PD ≥ 5 mm) in the two 
antimicrobial-groups as compared to  placebo41.
Microbiological results. Detection of the main periodontal pathogens A. actinomycetemcomitans and P. 
gingivalis as related to their presence/absence prior treatment are presented in Table 1. A. actinomycetemcomi-
tans was detectable at 6 and 12 months in a higher number of patients in the placebo group as opposed to the 
antimicrobial-groups (group B and C); moreover, antimicrobials were not able to completely eradicate (i.e. below 
3
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16322  | https://doi.org/10.1038/s41598-020-73054-8
www.nature.com/scientificreports/
the detection limit) this periodontal pathogen in neither of the antimicrobial-groups. Similar observations were 
seen for P. gingivalis (Table 1).
Nonetheless, patients initially positive on P. gingivalis showed at 6 months statistically significantly fewer 
residual deep sites (PD ≥ 6 mm) in the two antimicrobial-groups compared to the placebo group (p < 0.05); this 
was maintained up to 12 months in the 3-day antimicrobial-group (p < 0.05) (Table 2). Significantly more treated 
sites resulted in pocket closure (PD < 4 mm) at 6 months in the two antimicrobial-groups compared to placebo 
(p < 0.05, Table 2). The 3-day antimicrobial-group showed significantly more (p = 0.044) healed sites compared to 
placebo also at 12 months. However, no statistically significant differences were obtained between the two groups 
receiving antimicrobials (p > 0.05). Only patients positive on P. gingivalis at 6 months had statistically significantly 
more deep sites in the placebo group as opposed to the 3-day antimicrobial-group (p = 0.001).
Both initially negative and positive patients for A. actinomycetemcomitans showed at 6 months statistically 
significantly less deep sites in the two antimicrobial-groups compared to placebo. Nonetheless, only those initially 
negative had at 12 months still significantly less deep sites in the 3-day -group compared to placebo (Table 2). 
Similar findings were observed for the patients negative for A. actinomycetemcomitans at 6/12 months.
Patients initially negative on T. denticola had significantly less deep sites at 6 and 12 months in the 3-day 
antimicrobial-group compared to placebo, while those in the 7-day antimicrobial-group showed only at 6 months 
significantly less such sites. Subjects positive on T. denticola at 6 months had in both antimicrobial-groups 
significantly less deep sites than placebo, while at those positive at 12 months showed a borderline significance 
(p = 0.05) for the 3-day antimicrobial-group (Table 2).
Initial presence or absence (prior treatment) or at the follow-ups of A. actinomycetemcomitans, P. gingivalis 
or T. denticola did not have any influence on the number of sites reaching pocket closure neither at 6 nor at 
12 months (Table 2).
At 12 months compared to baseline, quantitative microbial analyses showed statistically significant reductions 
in the proportions of P. gingivalis, T. forsythia, C. rectus and F. allocis in all treatment groups (Table 3). T. denticola 
was statistically significantly reduced at 12 months compared to baseline only in the antimicrobial-groups, while 
A. actinomycetemcomitans was reduced only in the 7-day antimicrobial-group and only at the 6 months evalu-
ation; at 12 months, there were no significant reductions compared to baseline in none of the groups (p > 0.05). 
Nonetheless, group comparisons revealed no significant quantitative differences at baseline for neither of the 
microorganisms, with the exception of A. actinomycetemcomitans, which was present in significantly higher 
quantities in the placebo compared to the 3-day group (Table 3). Following, at 12 months, statistically significantly 
higher reductions in the mean counts of the P. gingivalis were seen in both antimicrobial-groups compared to 
placebo. F. nucleatum and F. allocis were statistically significantly reduced only in the 7-day AB group compared 
to placebo. Neither at 6 nor at 12 months, no statistically significant differences were seen between the two 
antibiotic groups for any of the microorganisms (p > 0.05, Table 2).
At 12 months statistically significantly, less patients were positive on P. gingivalis and F. allocis compared to 
baseline in the two antimicrobial-groups (Table 4), while T. denticola was less detectable in all treatment groups 
(p < 0.05). Detection of A. actinomycetemcomitans did not show any statistically significant reduction in any of 
Table 1.  Detection of A. actinomycetemcomitans and P. gingivalis. Detection of the periodontopathogens 
at baseline, 3, 6 and 12 months (number of subjects) in patients positive/negative before treatment foe each 
treatment group: Group A: Placebo, Group B: 3 days AMX + MET, Group C: 7 days AMX + MET (Aa: A. 
actinomycetemcomitans; Pg: P. gingivalis; m: months; Base: baseline; m: months; N: number of patients; “ + ”: 
subjects positive for the bacterium; “−” subjects negative for the bacterium).
Microorganism A. actinomycetemcomitans P. gingivalis
Timepoints
Group A
N = 26
Group B
N = 24
Group C
N = 25
Group A
N = 26
Group B
N = 24
Group C
N = 25
Subjects positive at base
Base 15 7 11 29 26 28
3 m+ 11 2 4 18 11 6
3 m− 4 5 7 11 15 22
6 m+ 9 4 5 19 12 6
6 m− 6 3 6 10 14 22
12 m+ 10 3 7 24 14 14
12 m− 5 4 4 5 12 14
Subjects negative at base
Base 15 23 20 1 4 3
3 m+ 4 1 6 1 1 1
3 m− 11 22 14 0 3 2
6 m+ 3 6 5 1 1 1
6 m− 12 17 15 0 3 2
12 m+ 4 6 8 1 2 0
12 m− 11 17 12 0 2 3
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Table 2.  Outcomes for residual deep sites and healed sites depending on the presence of A. 
actinomycetemcomitans, P. gingivalis and T. denticola. Mean number (N) of residual deep sites (PD ≥ 6 mm) and 
of sites achieving pocket closure (PD < 4 mm) at 6 and 12 m depending on the presence/absence at baseline, at 
6 or 12 months of the periodontal pathogens A. actinomycetemcomitans, P. gingivalis and T. denticola (Group 
A: Placebo, Group B: 3 days AMX + MET, Group C: 7 days AMX + MET; Aa: A. actinomycetemcomitans; Pg: P. 
gingivalis; m: months; Base: baseline; N: number of patients). Baseline, 6 m and 12 m data for the number of 
sites ≥ 6 mm of all patients had been previously published in Cosgarea et al. 2017.
Variables
Group A (N = 26)
Mean ± SD
Group B (N = 24)
Mean ± SD
Group C (N = 25)
Mean ± SD p (A–B) p (A–C) p (B–C)
PD ≥ 6 mm PD ≤ 3 mm PD ≥ 6 mm PD ≤ 3 mm PD ≥ 6 mm PD ≤ 3 mm
PD ≥ 
6 mm PD ≤ 3 mm PD ≥ 6 mm PD ≤ 3 mm PD ≥ 6 mm PD ≤ 3 mm
All 
patients N = 26 N = 26 N = 24 N = 24 N = 25 N = 25
Base 25.50 ± 17.36 – 29.37 ± 14.65 – 35.92 ± 17.58 – 1.000 – 0.098 – 0.592 –
6 m 8.92 ± 6.63 38.70 ± 19.10 2.08 ± 3.43 52.60 ± 19.60 5.00 ± 5.11 51.90 ± 19.00 < 0.001 0.039 0.001 0.051 0.303 1.000
12 m 5.19 ± 3.71 39.00 ± 17.30 1.66 ± 2.26 52.30 ± 19.20 4.52 ± 5.49 51.50 ± 19.90 0.003 0.044 0.917 0.059 0.068 1.000
Aa 
negative 
(Base)
N = 12 N = 12 N = 19 N = 19 N = 16 N = 16
6 m 6.83 ± 5.54 39.17 ± 20.92 2.53 ± 3.75 53.32 ± 18.45 4.94 ± 5.43 52.19 ± 19.17 0.005 0.160 0.086 0.254 0.924 1.000
12 m 4.92 ± 3.55 39.25 ± 17.75 1.47 ± 1.98 54.11 ± 18.3 4.06 ± 5.42 53.25 ± 21.12 0.019 0.124 0.664 0.187 0.302 1.000
Aa 
positive 
(Base)
N = 14 N = 14 N = 5 N = 5 N = 9 N = 9
6 m 9.57 ± 6.65 38.4 ± 18.3 4.00 ± 5.48 50.0 ± 26.11 4.33 ± 3.12 51.4 ± 19.9 0.008 0.840 0.047 0.428 0.886 1.000
12 m 4.71 ± 3.63 38.71 ± 1.758 2.00 ± 2.92 45.20 ± 23.18 4.56 ± 4.39 48.44 ± 18.2 0.603 1.000 1.000 0.709 0.924 1.000
Aa negative
At 6 m 7.94 ± 5.43 41.11 ± 21.44 2.31 ± 3.83 54 ± 10 ± 20.26 4.65 ± 5.34 52.51 ± 19.55 0.001 0.200 0.037 0.345 0.933 1.000
At 12 m 4.83 ± 3.47 41.30 ± 17.63 1.64 ± 2.22 51.51 ± 19.35 3.78 ± 5.07 56.22 ± 19.51 0.015 0283 0.487 0.065 0.560 1.000
Aa positive
At 6 m 8.90 ± 7.42 35.00 ± 15.09 1.20 ± 8.37 47.21 ± 18.17 4.88 ± 3.09 50.81 ± 19.07 0.005 0.630 0.030 0.204 1.000 1.000
At 12 m 4.75 ± 3.88 33.81 ± 16.41 1.00 ± 1.41 60.51 ± 21.92 5.43 ± 4.93 39.61 ± 16.39 0.355 0.283 1.000 0.065 0.303 1.000
Pg 
negative 
(Base)
N = 1 N = 1 N = 4 N = 4 N = 3 N = 3
6 m 7.00 12.00 0 ± 0 59.0 ± 20.69 3.33 ± 3.51 41.67 ± 20.31 0.196 0.288 0.840 0.799 0.549 0.958
12 m 6.00 18.00 0 ± 0 55.0 ± 18.89 4.67 ± 7.23 44.00 ± 30.51 1.000 0.690 1.000 1.000 0.774 1.000
Pg 
positive 
(Base)
N = 25 N = 25 N = 20 N = 20 N = 22 N = 22
6 m 8.36 ± 6.32 39.80 ± 18.74 2.50 ± 3.63 51.35 ± 19.75 4.91 ± 4.84 53.32 ± 18.89 < 0.001 0.144 0.003 0.055 0.748 1.000
12 m 4.76 ± 3.59 39.80 ± 17.11 1.90 ± 2.22 51.70 ± 19.71 4.18 ± 4.84 52.55 ± 18.79 0.013 0.106 0.700 0.064 0.272 1.000
Pg negative
At 6 m 9.67 ± 6.91 49.71 ± 19.87 2.20 ± 3.49 54.40 ± 19.15 4.71 ± 4.95 53.21 ± 19.89 0.003 x 0.028 x 0.771
At 12 m 3.50 ± 3.59 38.51 ± 14.77 1.00 ± 1.69 53.90 ± 19.75 3.89 ± 4.83 53.80 ± 21.59 0.376 0.255 1.000 0.226 0.186 1.000
Pg positive
At 6 m 7.59 ± 5.88 32.90 ± 16.51 1.89 ± 3.55 49.70 ± 21.31 4.75 ± 3.30 45.01 ± 13.39 0.001 1.000 0.153 1.000 1.000 1.000
At 12 m 5.39 ± 3.43 39.21 ± 18.72 2.56 ± 2.55 49.01 ± 19.12 5.33 ± 5.78 44.30 ± 11.60 0.095 0.492 1.000 1.000 0.556 1.000
Td 
negative 
(Base)
N = 3 N = 3 N = 0 N = 0 N = 1 N = 1
6 m 9.00 ± 8.18 36.01 ± 20.88 – – 0.00 ± 0.00 32.02 ± 0.00 – – 0.527 0.883 – –
12 m 5.33 ± 2.01 38.71 ± 24.68 – – 0.00 ± 0.00 35.00 ± 0.00 – – 0.412 0.909 – –
Td 
positive 
(Base)
N = 23 N = 23 N = 24 N = 24 N = 24 N = 24
6 m 8.22 ± 6.13 39.10 ± 19.39 2.08 ± 3.44 52.60 ± 19.66 4.92 ± 4.66 52.81 ± 18.96 < 0.001 0.058 0.001 0.054 0.499 1.000
12 m 4.74 ± 5.01 39.01 ± 16.88 1.58 ± 2.15 52.31 ± 19.21 4.42 ± 5.01 52.20 ± 19.98 0.008 0.055 1.000 0.056 0.092 1.000
Td negative
At 6 m 7.60 ± 7.04 43.20 ± 18.92 2.07 ± 3.55 55.55 ± 21.71 5.20 ± 4.90 49.41 ± 19.26 0.017 0.448 0.262 1.000 0.421 1.000
At 12 m 3.43 ± 3.18 44.03 ± 18.88 1.00 ± 1.69 56.61 ± 19.04 2.94 ± 4.25 55.30 ± 21.88 0.080 0.305 1.000 0.392 0.524 1.000
Td positive
At 6 m 8.75 ± 5.81 35.91 ± 19.36 2.09 ± 3.48 49.22 ± 17.31 2.80 ± 3.27 62.00 ± 15.76 < 0.001 0.220 0.004 0.027 1.000 0.606
At 12 m 6.42 ± 3.32 33.10 ± 13.75 2.56 ± 2.55 45.21 ± 18.38 6.56 ± 5.59 44.81 ± 14.36 0.050 0.257 1.000 0.292 0.225 1.000
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Variables
Group A
N = 26
Group B
N = 24
Group C
N = 25
p value 
Mann–Whitney
A–B
p value 
Mann–Whitney
A–C
p value 
Mann–Whitney
B–C
A. actinomycetemecomitans (× 105)
Base 0.70 ± 2.11 0.11 ± 0.54 1.92 ± 6.29 0.036s 0.471 0.204
3 m 0.37 ± 1.06 0.01 ± 0.05 s 1.86 ± 9.30 0.001hs 0.053 0.213
6 m 0.74 ± 2.76 0.02 ± 0.08 0.15 ± 0.73s 0.138 0.244 0.775
12 m 0.17 ± 0.48 0.74 ± 3.65 1.10 ± 4.79 0.104 0.961 0.098
Δ base-3 m 0.35 ± 2.3 0.10 ± 0.48 0.34 ± 5.90 0.652 0.624 0.839
Δ base-6 m − 0.015 ± 1.56 0.10 ± 0.50 1.57 ± 5.77 0.971 0.617 0.672
Δ base-12 m 0.65 ± 2.18 − 0.61 ± 3.04 1.34 ± 8.63 0.738 0.600 0.640
Δ 3 m–6 m − 0.38 ± 2.67 − 0.004 ± 0.01 1.76 ± 8.71 0.114 0.805 0.128
Δ 3 m–12 m − 0.071 ± 0.41 − 0.73 ± 3.59 1.14 ± 11.47 0.617 0.429 0.465
Δ 6 m–12 m 0.58 ± 2.88 − 0.76 ± 3.65 − 1.01 ± 5.05 0.806 0.317 0.289
P. Gingivalis (× 106)
Base 5.06 ± 10.85hs 4.65 ± 12.81hs 9.42 ± 26.45hs 0.124 0.971 0.266
3 months 0.33 ± 1.50hs 0.52 ± 2.09s 0.01 ± 0.07hs 0.232 < 0.0001hs 0.014s
6 months 0.31 ± 1.08hs 1.23 ± 5.92hs 0.001 ± 0.006hs 0.037s < 0.0001hs 0.078
12 m 0.13 ± 0.25hs 0.07 ± 0.19hs 0.012 ± 0.035hs 0.033s < 0.0001hs 0.210
Δ base-3 m 4.89 ± 10.84 4.13 ± 13.05 10.41 ± 28.26 0.158 0.902 0.155
Δ base-6 m 4.89 ± 10.90 3.80 ± 14.66 9.98 ± 27.29 0.142 0.613 0.054
Δ base-12 m 3.81 ± 6.51 4.06 ± 13.07 11.84 ± 29.75 0.149 0.509 0.060
Δ 3 m–6 m 0.022 ± 0.05 − 0.63 ± 5.90 0.01 ± 0.07 0.479 0.206 0.838
Δ 3 m–12 m 0.28 ± 1.62 0.58 ± 2.36 0.005 ± 0.09 0.204 0.312 0.479
Δ 6 m–12 m 0.19 ± 1.16 1.28 ± 6.32 − 0.01 ± 0.034 0.550 0.565 0.784
T. denticola (× 106)
Base 0.30 ± 0.57 0.23 ± 0.30 0.76 ± 1.81 0.367 0.207 0.634
3 m 0.052 ± 0.14s 0.01 ± 0.035hs 0.02 ± 0.05hs 0.085 0.081 0.694
6 m 0.05 ± 0.14s 0.06 ± 0.22hs 0.03 ± 0.08hs 0.047s 0.012s 0.421
12 m 0.16 ± 0.48 0.03 ± 0.07hs 0.007 ± 0.016hs 0.256 0.103 0.644
Δ base-3 m 0.25 ± 0.62 0.22 ± 0.30 0.85 ± 1.93 0.062 0.057 0.424
Δ base-6 m 0.25 ± 0.59 0.19 ± 0.39 0.78 ± 1.88 0.194 0.126 0.692
Δ base-12 m 0.058 ± 0.57 0.21 ± 0.29 0.94 ± 2.03 0.103 0.008s 0.149
Δ 3 m–6 m − 0.006 ± 0.19 − 0.05 ± 0.19 − 0.16 ± 0.06 0.763 0.428 0.334
Δ 3 m–12 m − 0.11 ± 0.53 − 0.02 ± 0.07 − 0.000 ± 0.03 0.658 0.727 0.277
Δ 6 m–12 m − 0.089 ± 0.52 0.034 ± 0.009 0.009 ± 0.05 0.683 0.494 0.733
T. forsythia (× 106)
Base 6.13 ± 12.01 7.17 ± 10.41 11.90 ± 28.24 0.628 0.589 0.988
3 m 1.16 ± 2.85s 0.04 ± 0.16hs 0.027 ± 0.11hs 0.031s 0.046s 0.928
6 m 30.77 ± 160.26s 0.21 ± 0.60hs 0.98 ± 3.56s 0.040s 0.012s 0.499
12 m 0.42 ± 0.99hs 0.65 ± 2.43s 0.36 ± 1.38hs 0.432 0.674 0.238
Δ base-3 m 4.96 ± 12.82 7.13 ± 10.44 13.27 ± 30.08 0.307 0.195 0.686
Δ base-6 m − 24.42 ± 161.92 6.79 ± 11.01 11.56 ± 29.76 0.422 0.234 0.646
Δ base-12 m 6.09 ± 13.02 6.08 ± 11.39 12.65 ± 31.60 0.918 0.402 0.417
Δ 3 m–6 m − 30.98 ± 163.26 − 0.16 ± 0.49 − 1.07 ± 3.76 0.783 0.645 0.516
Δ 3 m–12 m 0.98 ± 3.31 − 0.60 ± 2.45 − 0.34 ± 1.49 0.213 0.785 0.248
Δ 6 m–12 m 38.37 ± 179.99s − 0.44 ± 2.61 0.88 ± 4.43 0.075 0.111 0.774
P. micra (× 106)
Base 0.112 ± 0.254 0.308 ± 0.736 0.276 ± 0.780 0.271 0.367 0.937
3 m 0.180 ± 0.476 0.252 ± 1.032s 0.045 ± 0.137hs 0.052 0.003s 0.175
6 m 0.177 ± 0.380 0.127 ± 0.467s 0.031 ± 0.086s 0.021s < 0.0001hs 0.215
12 m 0.311 ± 0.587 0.112 ± 0.272 0.206 ± 0.869s 0.601 0.244 0.435
Δ base-3 m − 0.064 ± 0.55 0.05 ± 0.65 0.24 ± 0.85 0.168 0.074 0.678
Δ base-6 m − 0.065 ± 0.45 0.14 ± 0.80 0.26 ± 0.81 0.009s 0.009s 0.987
Δ base-12 m − 0.23 ± 0.57 0.25 ± 0.86 0.12 ± 1.26 0.146 0.020s 0.543
Δ 3 m–6 m 0.000 ± 0.59 0.16 ± 0.99 0.13 ± 0.15 0.525 0.425 0.827
Δ 3 m–12 m − 0.22 ± 0.67 0.20 ± 1.21 − 0.22 ± 0.93 0.881 0.934 0.550
Δ 6 m–12 m − 0.12 ± 0.72 0.026 ± 0.58 − 0.19 ± 0.92 0.474 0.262 0.899
Continued
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the treatment groups neither at 6 nor at 12 months (p > 0.05, Table 4). Group comparisons revealed that even 
if at 6 months several bacteria (P. gingivalis, T. denticola, T. forsythia, F. nucleatum, C. rectus, F. allocis) were 
statistically significantly less detectable in the 7-day antimicrobial-group compared to placebo, at 12 months no 
significant differences were registered between the groups. Only P. gingivalis was significantly less detectable in 
both antimicrobial-groups compared to placebo while F. allocis only in the 7-day antimicrobial-group (Table 4).
Immunomarkers. Compared to baseline, IL-1β was statistically significantly reduced at 3 and 6 months in 
the two antimicrobial-groups. However, this was maintained up to 12 months only in the 7-day AB (Table 5). 
Nonetheless, at baseline, statistically significantly higher counts of IL-1β were detected in group C compared 
to the control group. At 12 months, only MMP-8 was statistically significantly reduced in the 7-day antimicro-
bial-group. Intergroup comparisons revealed no statistically significant differences between the three groups at 
12 months (Table 5).
Table 6 depicts the results of the Poisson regression analyses showing that antimicrobials, female gender, 
smoking status, severe forms periodontitis (≥ 10 sites with PD ≥ 6 mm at baseline) and initial CAL-loss, BOP at 
baseline, detection of A. actinomycetemcomitans and T. denticola at 12 months as well as initial detection if IL-1β 
statistically significantly influenced the residual number of deep sites at 12 months (p < 0.05).
Variables
Group A
N = 26
Group B
N = 24
Group C
N = 25
p value 
Mann–Whitney
A–B
p value 
Mann–Whitney
A–C
p value 
Mann–Whitney
B–C
F. Nucleatum (× 106)
Base 2.29 ± 1.66 3.18 ± 4.21 3.70 ± 4.06 0.918 0.341 0.554
3 m 1.29 ± 1.51s 0.75 ± 1.26hs 0.54 ± 0.74hs 0.040s 0.018s 0.923
6 m 2.12 ± 2.58 0.96 ± 1.36hs 0.51 ± 0.93hs 0.027s < 0.0001hs 0.132
12 m 2.25 ± 2.08 9.44 ± 36.18 1.01 ± 1.40hs 0.516 0.011s 0.137
Δ base-3 m 1.02 ± 1.92 2.43 ± 4.11 3.32 ± 4.29 0.154 0.031s 0.330
Δ base-6 m 0.13 ± 3.11 2.42 ± 4.39 3.04 ± 4.33 0.043s 0.009s 0.399
Δ base-12 m 0.25 ± 2.68 − 6.02 ± 37.11 3.45 ± 4.71 0.364 0.003s 0.080
Δ 3 m–6 m − 0.93 ± 2.21 − 0.11 ± 0.82 0.02 ± 1.07 0.359 0.062 0.244
Δ 3 m–12 m − 0.96 ± 1.87 − 8.55 ± 36.33 − 0.44 ± 1.16 0.670 0.159 0.509
Δ 6 m–12 m − 0.21 ± 2.63 − 8.83 ± 37.15 − 0.55 ± 0.99 0.177 0.401 0.440
C. Rectus (× 106)
Base 0.42 ± 0.36 0.56 ± 0.58 0.84 ± 0.89 0.652 0.072 0.257
3 m 0.18 ± 0.27s 0.082 ± 0.13hs 0.067 ± 0.11hs 0.061 0.030s 0.658
6 m 0.31 ± 0.68 0.12 ± 0.24hs 0.082 ± 0.24hs 0.082 0.002s 0.099
12 m 0.21 ± 0.23s 9.46 ± 45.61s 0.15 ± 0.23hs 0.105 0.221 0.917
Δ base-3 m 0.23 ± 0.48 0.48 ± 0.59 0.84 ± 0.96 0.219 0.009s 0.157
Δ base-6 m 0.10 ± 0.77 0.47 ± 0.67 0.67 ± 0.83 0.194 0.009s 0.212
Δ base-12 m 0.20 ± 0.49 − 8.85 ± 45.68 0.79 ± 0.98 0.201 0.023s 0.375
Δ 3 m–6 m − 0.13 ± 0.68 − 0.028 ± 0.18 − 0.017 ± 0.23 0.768 0.889 0.475
Δ 3 m–12 m − 0.04 ± 0.24 − 9.37 ± 45.61 − 0.088 ± 0.25 0.806 0.404 0.522
Δ 6 m–12 m 0.15 ± 0.76 − 9.74 ± 46.58 − 0.10 ± 0.22 0.982 0.311 0.310
F. Allocis (× 106)
Base 1.60 ± 3.17 1.99 ± 3.52 2.49 ± 9.09 0.506 0.762 0.242
3 m 0.31 ± 0.76hs 0.058 ± 0.17hs 0.015 ± 0.063hs 0.002s < 0.0001hs 0.762
6 m 0.27 ± 0.53hs 0.11 ± 0.25hs 0.033 ± 0.12hs 0.085 0.001hs 0.123
12 m 0.071 ± 0.18hs 0.026 ± 0.059hs 0.021 ± 0.077hs 0.553 0.025s 0.083
Δ base-3 m 1.32 ± 3.06 1.93 ± 3.55 2.66 ± 9.75 0.231 0.594 0.243
Δ base-6 m 1.38 ± 3.22 1.86 ± 3.75 2.56 ± 9.41 0.381 0.657 0.555
Δ base-12 m 1.64 ± 3.39 2.12 ± 3.81 2.95 ± 10.33 0.303 0.992 0.293
Δ 3 m–6 m 0.04 ± 0.78 − 0.05 ± 0.14 − 0.02 ± 0.14 0.128 0.415 0.179
Δ 3 m–12 m 0.28 ± 0.75 0.04 ± 0.16 − 0.004 ± 0.11 0.149 0.054 0.926
Δ 6 m–12 m 0.26 ± 0.60 0.10 ± 0.23 − 0.007 ± 0.026 0.270 0.013s 0.388
Table 3.  Quantitative microbiological results. Mean values and group comparisons (Mann Whitney U 
for inter-group comparisons, Wilcoxon Signed Ranks test) for intra-group comparisons between various 
timepoints) for microbiological parameters (mean ± SD) (Group A: Placebo, Group B: 3 days AMX + MET, 
Group C: 7 days AMX + MET; sstatistical significant p values 0.001 < p < 0.05; hshighly statistically significant 
values p ≤ 0.001; Base: baseline, m: months, Δ: change).
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Discussion
The present analyses have evaluated the effect of two systemic antibiotic protocols adjunctive to SD over SD alone 
on the microbial and inflammatory parameters. Furthermore, the clinical efficacy in terms of pocket closure 
(PD < 4 mm) and residual deep sites (PD ≥ 6 mm) at 12 months as related to the presence/absence of P. gingivalis, 
T. denticola and A. actinomycetemcomitans prior to treatment or at follow-ups was also assessed.
At 6 months, all three treatment protocols succeeded in reducing significantly the counts of P. gingivalis, T. 
forsythia, T. denticola, P. micra and F. allocis. However, these substantial bacterial load reductions were maintained 
up to 12 months in all three groups only for P. gingivalis, T. forsythia and F. alocis. The pathogens T. denticola, 
P. micra and F. nucleatum were still statistically significantly reduced after 1 year only in the two antimicrobial-
groups. Moreover, the quantitative reductions of the keystone pathogen P. gingivalis were statistically significantly 
higher at all timepoints in the two antimicrobial-groups as compared to placebo. Considering the fact that the 
baseline plaque-scores did not differ statistically significantly between the three treatment  groups41, the better 
Table 4.  Qualitative microbial analysis. Detection frequency of periodontopathogenic microorganisms 
(Group A: Placebo, Group B: 3 days AMX + MET, Group C: 7 days AMX + MET; sstatistical significant p values 
0.001 < p < 0.05; hshighly statistically significant values p ≤ 0.001; Base: baseline, m: months, Δ: change).
Variables
Group A 
(n = 26)
n/%
Group B (n = 24)
n/%
Group C (n = 25)
n/% p (A–B) p (A–C) p (B–C)
A. actinomycetemcomitans
Base 15/50 7/23.3 11/35.5 0.032s 0.259 0.305
3 m 15/50 3/10 10/32.3 0.001s 0.165 0.034s
6 m 12/40 10/33.3 10/32.3 0.599 0.537 0.930
12 m 14/46.7 9/30 15/48.4 0.190 0.895 0.146
P. gingivalis
Base 29/96.7 26/86.7 28/90.3 0.168 0.325 0.661
3 m 19/63.3s 12/40hs 7/22.6hs 0.073 0.001s 0.147
6 m 20/66.7s 13/43.3hs 7/22.6hs 0.071 < 0.000hs 0.087
12 m 25/83.3 16/53.3s 14/54.2hs 0.012s 0.001hs 0.531
T. denticola
Base 27/90 30/100 30/96.8 0.078 0.293 0.329
3 m 17/56.7s 12/40hs 12/38.7hs 0.203 0.166 0.920
6 m 20/66.7s 15/50hs 10/32.3hs 0.197 0.007s 0.164
12 m 19/63.3s 15/50hs 16/51.6hs 0.305 0.363 0.902
T. forsythia
Base 23/76.7 21/70 21/67.7 0.567 0.445 0.852
3 m 10/33.3s 3/10hs 7/22.6hs 0.028s 0.357 0.191
6 m 15/50 10/33.3hs 6/19.4s 0.197 0.011s 0.221
12 m 12/40s 16/53.3 12/38.7s 0.309 0.920 0.259
F. nucleatum
Base 29/96.7 30/100 29/93.5 0.321 0.581 0.162
3 m 27/90 22/73.3s 26/83.9 0.098 0.487 0.323
6 m 28/93.3 23/76.7s 21/67.7s 0.073 0.011s 0.445
12 m 29/96.7 27/90 27/87.1 0.310 0.179 0.727
P. micra
Base 27/90 29/96.7s 26/83.9s 0.309 0.487 0.096
3 m 24/80 17/56.7s 14/45.2hs 0.053 0.004s 0.377
6 m 26/86.7 19/63.3s 13/41.9 0.037s < 0.0001hs 0.097
12 m 22/73.3 23/76.7 21/67.7 0.770 0.639 0.445
C. rectus
Base 27/90 25/83.3 28/90.3 0.456 0.967 0.427
3 m 24/80 16/53.3s 17/54.8hs 0.029s 0.037s 0.908
6 m 25/83.3 23/76.7 18/58.1s 0.527 0.031s 0.126
12 m 26/86.7 22/73.3 24/77.4 0.203 0.356 0.717
F. allocis
Base 27/90 28/93.3 25/80.6 0.647 0.311 0.147
3 m 23/76.7 13/43.3hs 15/48.4s 0.008s 0.022s 0.698
6 m 23/76.7 19/63.3s 15/48.4s 0.267 0.023s 0.247
12 m 22/73.3 20/66.7s 15/48.4s 0.581 0.047s 0.154
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microbial outcomes for the antimicrobial-groups may probably be attributed to the systemic intake of antimi-
crobials and not to a supra- and subgingival manual biofilm reduction. These results corroborate to those of 
other studies, where AMX + MET led to statistically significantly higher reductions of the bacterial counts of P. 
gingivalis, T. forsythia or T. denticola after 3, 6 and/or 12  months18,23,52–55.
Contrary to the findings of other research  groups54,55, A. actinomycetemcomitans could not be significantly 
reduced in any of the groups at 12 months. This may be related to differences in detection methods (i.e. culturing 
techniques, checkerboard DNA-DNA hybridisation vs. rtPCR)55. However, significant quantitative reductions 
of A. actinomycetemcomitans were observed at 3 and 6 months respectively only in the AB groups, being in 
line with reports of other  authors23,53,56. Moreover, confirming our results, Eick et al.52, showed no statistically 
Table 5.  Quantitative immunological analysis. Mean levels and group comparisons (one way ANOVA, 
Bonferroni correction for inter- and intra-group comparisons between different timepoints) of immunological 
(IL-1β, IL-10, TNF α, MMP8) parameters (mean ± SD) (Group A: Placebo, Group B: 3 days AMX + MET, 
Group C: 7 days AMX + MET; sstatistical significant p values; IL: Interleukin; TNF: tumor necrosis factor; 
MMP: matrix metallo protease; Base: baseline, m: months, Δ: change).
Variables
Group A
N = 26
Group B
N = 24
Group C
N = 25
Group comparisons
p (A–B) p (A–C) p (B–C)
IL 1β
Base 18.00 ± 18.39 26.57 ± 20.46 34.54 ± 24.48 0.275 0.009s 0.322
3 m 9.21 ± 11.71 10.66 ± 12.83hs 8.00 ± 12.04hs 0.892 0.926 1.000
6 m 11.25 ± 15.96 10.00 ± 10.67s 9.32 ± 15.55hs 0.947 0.868 1.000
12 m 18.36 ± 20.62 18.01 ± 20.76 14.31 ± 14.47s 0.998 0.728 1.000
Δ base-3 m 7.06 ± 21.29 15.75 ± 18.10s 28.65 ± 26.30s 0.298 0.001hs 0.091
Δ base-6 m 7.98 ± 26.23 12.09 ± 19.35s 27.21 ± 29.25s 0.833 0.016s 0.107
Δ base-12 m − 2.64 ± 25.54 9.03 ± 28.12 21.91 ± 29.59s 0.321 0.007s 0.320
Δ 3 m–6 m − 1.80 ± 19.26 0.86 ± 12.60 − 2.22 ± 12.27 0.802 0.994 1.000
Δ 6 m–12 m − 7.29 ± 27.48 − 10.10 ± 23.82s − 3.23 ± 19.92s 0.917 0.833 0.981
IL-10
Base 0.65 ± 1.65 0.29 ± 0.77 0.33 ± 0.96 0.476 0.546 1.000
3 months 2.30 ± 4.39 0.66 ± 1.32 0.80 ± 2.39 0.092 0.145 1.000
6 months 2.29 ± 3.99 0.93 ± 2.75 0.54 ± 2.24 0.243 0.089 1.000
12 m 0.93 ± 3.85 1.06 ± 3.48 2.22 ± 5.06 0.993 0.528 0.989
Δ base-3 m − 1.62 ± 4.80 − 0.39 ± 1.51 − 0.52 ± 2.01 0.297 0.364 1.000
Δ base-6 m − 1.61 ± 4.40 − 0.68 ± 2.97 − 0.19 ± 2.26 0.576 0.248 1.000
Δ base-12 m − 0.11 ± 4.19 − 0.81 ± 3.73 − 1.82 ± 5.34 0.852 0.377 1.000
Δ 3 m–6 m 0.09 ± 6.56 − 0.21 ± 2.89 0.25 ± 2.05 0.964 0.990 1.000
Δ 6 m–12 m 1.89 ± 6.40 0.48 ± 3.75 − 1.25 ± 5.65 0.643 0.121 0.797
IL-8
Base 15.84 ± 18.73 23.48 ± 24.74 30.36 ± 37.26 0.553 0.115 1.000
3 m 16.67 ± 23.13 15.98 ± 17.89 9.36 ± 13.72s 0.989 0.308 0.343
6 m 27.09 ± 33.23s 15.00 ± 15.07 12.32 ± 14.40s 0.130 0.043s 1.000
12 m 21.34 ± 23.71 18.18 ± 24.22 22.12 ± 24.39 0.891 0.993 1.000
Δ base-3 m − 0.47 ± 29.13 6.94 ± 21.67 21.89 ± 38.27s 0.353 0.218 0.199
Δ base-6 m − 13.55 ± 37.03 4.64 ± 26.09 19.00 ± 40.43s 0.998 0.177 0.424
Δ base-12 m − 7.67 ± 28.96 0.46 ± 27.50 8.78 ± 40.19 0.096 0.007s 1.000
Δ 3 m–6 m 11.92 ± 38.47 0.34 ± 19.13 − 1.97 ± 19.97 0.213 0.951 1.000
Δ 6 m–12 m 5.57 ± 34.78 − 2.35 ± 25.72 − 11.11 ± 19.96 0.308 0.564 0.808
MMP 8
Base 2471.56 ± 1815.96 3335.60 ± 2596 ± 56 4000.64 ± 2320.63 0.313 0.027s 0.494
3 m 1153.20 ± 1313.64s 3096.09 ± 4814.24 1475.57 ± 1017.55hs 0.038s 0.913 0.126
6 m 1758.83 ± 1489.02 2437.04 ± 2862.80 1886.99 ± 1225.48hs 0.415 0.967 0.904
12 m 2167.45 ± 1299.59 2013.63 ± 1281.73 1774.55 ± 1260.12hs 0.907 0.527 1.000
Δ base-3 m 1299.79 ± 24.03.82s 140.72 ± 4063.02 2719.78 ± 2844.77s 0.353 0.218 0.009s
Δ base-6 m 654.65 ± 2663.64 704.47 ± 4608.73 2234.41 ± 2454.42s 0.998 0.177 0.285
Δ base-12 m − 110.74 ± 1754.95 1367.94 ± 2912.39s 2039.03 ± 2480.36s 0.096 0.007s 0.999
Δ 3 m–6 m − 669.59 ± 1867.51s 737.49 ± 4668.56 − 422.41 ± 1586.20 0.213 0.951 0.497
Δ 6 m–12 m − 471.55 ± 1933.76 473.00 ± 3078.88 182.99 ± 866.14 0.308 0.564 1.000
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significant reduction of A. actinomycetemcomitans after 3–6 months after SD with systemic AMX + MET (each 
500 mg 3TID for 7 days) neither in patients with chronic nor aggressive periodontitis.
At 12 months, antimicrobials were not able to supress A. actinomycetemcomitans or P. gingivalis below the 
detection limit. Almost half of the subjects initially positive on P. gingivalis were still positive at 12 months in 
the two antimicrobial-groups, while 82% of the patients in the placebo group were still positive. The discrepancy 
between the groups was smaller for A. actinomycetemcomitans. These results are in line with those of Eick et al.52, 
showing at 3–6 months post-therapeutically statistically significant reductions of several periodontal pathogens 
(i.e. P. gingivalis, T. forsythia, T. denticola, P. intermedia, e.t.c.) except for A. actinomycetemcomitans. Despite the 
fact that statistically significant reductions were detected for these pathogens, there were still non-neglectable 
percentages of patients harbouring these  bacteria52. This corroborates with detection frequencies observed in 
our study. Moreover, previous reports from other authors have reported that A. actinomycetemcomitans had not 
been completely eliminated by subgingival  debridement6.
Another explanation would be that, in light of the worldwide indiscriminate use of antimicrobials and implic-
itly increasing antibiotic  resistance44, patients may harbour nowadays more resistant strains of these periodontal 
pathogens as compared to subjects in earlier studies. It has been shown that the reservoir for antibiotic-resistant 
genes has been increasing over the past  century12,45. This fact adds on to the capacity of the oral microbiota to 
transfer antimicrobial  resistance46–49. For example, Streptococcus cristaceus has acquired in vivo doxycycline resist-
ance from a resistant strain of Streptococcus oralis, both isolated from the subgingival biofilm of patients under 
doxycycline  therapy50. So far, no such direct evidence exists for bacteria of the red complex or A. actinomycetem-
comitans, but it is very likely that these bacteria as well may have acquired in time resistance to commonly used 
antimicrobials. Additionally, other authors have already reported high percentages (74.2%) of patients with peri-
odontal pathogens resistant to at least one of the most commonly used antimicrobials in periodontal  treatment57.
Interestingly, several patients initially negative for A. actinomycetemcomitans became positive at 12 months. 
This may be attributed to the nature of this pathogen being a facultative aerobic bacterium. Pooled samples of 
subgingival plaque were taken from the deepest site in each quadrant, where most probably anaerobic patho-
gens were present in higher proportions. After therapy, those sites reduced their depths, resulting in shallow 
pockets with more aerobic conditions, making thus the detection of A. actinomycetemcomitans more probable. 
Additionally, the sampling method may also have had an impact on the microbiological results, which may pos-
sibly reflect an artefact. With the employed sampling strategy, only the chosen deep sites are being examined 
Table 6.  Regression analysis for factors influencing the residual number of deep periodontal pockets. Factors 
influencing the number of residual deep sites (PD ≥ 6 mm) at 12 months as related to placebo (Group A: 
Placebo, Group B: 3 days AMX + MET, Group C: 7 days AMX + MET). (Poisson regression analysis; PD: pocket 
depth, CAL: clinical attachment level, BOP: bleeding on probing, GBI: gingival bleeding  index70, FMPS: full-
mouth plaque score after O’Leary66, A.a.: Aggregatibacter actinomycetemcomitans; T.d.: Treponema denticola; 
P.g.: Porphyromonas gingivalis; F.a.: Filifactor alocis; IL-1β = Interleukin-1Beta; sstatistical significant p values. 
Reference categories are: Group A, Male, Non-Smoker (Exp. Coefficient equals)).
Variables Exp. coefficient 95% CI p value
Group B (AB for 3 days) 0.24 0.14–0.41 < 0.001s
Group C (AB for 7 days) 0.53 0.32–0.87 0.012s
Gender 1.39 0.99–1.95 0.052
Smoker 1.36 0.23–0.54 < 0.001s
≥ 10 sites with PD ≥ 6 mm at baseline 0.55 0.30–0.99 0.046s
BOP baseline 0.21 0.11–0.39 < 0.001s
BOP at 12 m 3.30 0.71–15.30 0.126
GBI baseline 1.04 0.98–1.09 0.150
GBI at 12 m 1.46 0.37–5.68 0.585
FMPS baseline 1.02 0.98–1.05 0.241
FMPS at 12 m 0.73 0.21–2.51 0.619
Mean PD baseline 1.01 0.67–1.51 0.946
Mean CAL baseline 1.41 1.17–1.69 < 0.001s
A.a positive at baseline 1.04 0.73–1.47 0.827
A.a positive at 12 m 1.05 0.71–1.55 0.797
T.d. positive at baseline 1.01 0.40–2.56 0.974
T.d. positive at 12 m 2.17 1.32–3.56 0.002s
P.g. positive at baseline 0.82 0.43–1.58 0.566
P.g. positive at 12 m 1.06 0.67–1.68 0.797
F.a. positive at baseline 1.33 0.76–2.29 0.287
F.a. positive at 12 m 1.37 0.85–2.22 0.186
IL-1β positive at baseline 1.01 1.00–1.03 0.002s
IL-1β positive at 12 m 0.99 0.98–1.01 0.158
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and their results are being extrapolated on the entire mouth. It is well known that high levels and proportions 
of periodontal pathogens may also be present in shallow gingival  crevices58 which had not been assessed. Since 
A. actinomycetemcomitans is facultative anaerobic, it may have as well been present in more shallow sites as 
opposed to those here analysed (PD ≥ 6 mm), thus leading to false negative results. Another possibility would 
be the reemergence of A. actinomycetemcomitans from other anatomical areas in the oro-pharynx. Data show 
that A. actinomycetemcomitans is presents even in periodontally healthy patients in high numbers on the cheek 
mucosa (62%), in saliva (59%) and tonsils (41%)59. For P. gingivalis, the majority of the patients in the placebo 
group remained positive at 12 months (83%, Table1), while about 50% of the patients in the two antimicrobial-
groups became negative; thus, statistically significantly fewer patients in the AB groups harboured this pathogen 
at 12 months as compared to placebo. These results are in line with those of Rooney et al. who obtained a rare 
recovery of A. actinomycetemcomitans and P. gingivalis19. Additionally, data from a recent systematic  review60 
indicate comparable percental reductions in the subjects positive on P. gingivalis and A. actinomycetemcomi-
tans: P. gingivalis difference for percental detection rates between test and control group in Dakic et al.: 28% 
(3 months), 32% (6 months), 34% (12 months) versus our study: 20–40% (3, 6, 12 months); respectively for A. 
actinomycetemcomitans in Dakic et al.: 30% (3 months), 25% (6 months) with no difference between the groups 
at 12  months60. Comparable results were seen in our study: 10–40% difference between the groups at 3 and 
6 months, with a slight (10%) to no difference at 12 months between placebo and the two antimicrobial-groups.
From a clinical point of view, statistically significantly fewer residual deep sites (PD ≥ 6 mm) and more sites 
reached pocked closure at 12 months in the 3-day antimicrobial-group as opposed to placebo. Interestingly, 
this could not be observed for the 7-day AB-protocol. Analysing the impact of A. actinomycetemcomitans or P. 
gingivalis on these clinical parameters, only patients initially negative for A. actinomycetemcomitans and initially 
positive for P. gingivalis exhibited at 12 months significantly less residual deep sites as opposed to placebo; none-
theless, at 6 months, A. actinomycetemcomitans positive patients showed in both antimicrobial-groups statisti-
cally significantly fewer residual sites compared to placebo. This underlines the fact that antimicrobials had a 
statistically significant positive effect also on patients negative for this periodontal pathogen compared to those 
not receiving the medication, and is in line with reports of other  studies23. These results are further supported 
by the recent findings of a systematic review that stressed out the efficacy of AMX + MET in improving clinical 
outcomes irrespective of the initial detection of A. actinomycetemcomitans15.
Moreover, the results of the present regression analysis showed that neither presence of A. actinomycet-
emcomitans and P. gingivalis at baseline nor at 12 months were associated with a higher risk for residual deep 
sites at 12 months (p < 0.05). These results corroborate those of Mombelli et al., who have also observed that 
the presence/absence of A. actinomycetemcomitans did not influence the effect of antimicrobials on persisting 
active sites with PD > 4  mm56. Antimicrobials seemed to be highly efficient in both A. actinomycetemcomitans 
positive and negative patients. Additionally, antimicrobial-groups had significantly more sites reaching pocket 
closure (PD < 4 mm) at 6 months compared to placebo which is in line with Kolakovic et al.61, who obtained 
in a meta-analysis a 4.43 higher chance for pocket closure at 6 months in the AMX + MET group compared to 
control. Moreover, the results in our study were maintained up to 1 year. Further subgroup analyses based on 
the presence/absence of selected periodontal pathogens could not show any statistically significant influence on 
the number of sites reaching pocket closure (p > 0.05), despite the fact that the patients receiving placebo had 
fewer healed sites (PD < 4 mm) as opposed to those receiving systemic medication.
Nonsurgical periodontal therapy with the two antibiotic protocols yielded a decrease in the levels of proin-
flammatory markers (IL-1β, IL-8, MMP-8) and an increase of the cytokine IL-10, that is associated with peri-
odontal health. Cytokine analysis resulted in a significant reduction of the proinflammatory immunomarker 
IL-1β at 3 and 6 months compared to baseline only in the two antimicrobial-groups. This could be observed in 
the 7-day antimicrobial-group also at 12 months, which however, had at baseline significantly higher levels of 
IL-1β. Additionally, the initial detection of IL-1β was shown to statistically significantly influence the residual 
number of deep sites at 12 months. The other proinflammatory cytokines (IL-8, MMP-8) showed reductions at 
6 and 12 months only in the two antimicrobial-groups. Nonetheless, these reductions did not reach statistical 
significance except for MMP-8, that was statistically significantly reduced compared to baseline in the 7-day 
antimicrobial-group; however, MMP-8 intergroup comparisons revealed no significant differences between the 
three groups at 12 months. These results compare well to those of Jentsch et al., where slightly higher median 
values for IL-1β and comparable results for MMP-8 were reported for the AMX + MET group at 3 and 12 months 
 respectively62.
The present cytokine reductions in the two antimicrobial-groups, may indeed account for the additional 
general anti-inflammatory effect of systemic antimicrobials, especially since no statistically significant group 
differences for baseline plaque scores had been  detected41.
The current study represents a secondary analysis of the microbiological and inflammatory data of a clini-
cally designed RCT 33,41, which may be a limitation for the power of the current results. Considering the fact 
that the study was initially designed to find a difference between the control and the test groups for a clinical 
parameter (5 sites with PD ≥ 6 mm), the presented results and subgroup analyses should be interpreted with 
caution. Nevertheless, these microbiologic and immunologic data corroborate the primary clinical outcomes of 
the present  trial33,41 supporting the finding that both antibiotic protocols adjunctive to mechanical debridement 
elicit better clinical, microbiological and immunological effects in severe forms of chronic periodontitis (stage 
III-IV, grade B). It is important to emphasize that the study was designed to evaluate the efficacy of the two 
antibiotic regimes adjunctive to non-surgical periodontal therapy compared to mechanical debridement alone. 
The protocol had not been designed to determine the equivalence or non-inferiority of the use of a 3-day over 
the 7-day antibiotic protocol adjunctive to mechanical debridement and thus no clear clinical recommendations 
related to the preferential use of a 3-day AB course over a 7-day one can be made. Moreover, considering the 
global increase in antimicrobial resistance, antimicrobial usage adjunctive to non-surgical periodontal therapy 
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should be carefully taken prescribed only in selected patients with generalised severe forms of periodontitis that 
may really profit from  it63.
In conclusion, the present data indicate that the systemic use of both 3- and 7- day AMX + MET adjunctive 
to non-surgical periodontal therapy may induce superior microbiological outcomes compared to subgingival 
debridement alone. The two investigated antibiotic protocols led to comparable microbiological and inflamma-
tory results.
Methods
This study was a prospective, randomized, placebo controlled, double-masked clinical trial. Following hypoth-
esis was tested: “the systemic use of AMX and MET administered for 3 or 7 days as adjunct to SD leads to 
superior clinical results compared with SD alone”33. The clinical results after 6 and 12 months were previously 
 published41. The study protocol (according to the Declaration of Helsinki 1964, revision 2008) was approved 
by the Ethical Committee of the Faculty of Medicine and Pharmacy of Cluj-Napoca (Trial registration number 
#514/09.01.2012, registration date: 20.02.2012) and was registered in the ISRCTN registry (trial registration 
number: ISRCTN17605083, registration date: 16.6.2015, https ://www.isrct n.com/ISRCT N1760 5083).
Subjects and clinical protocol. The clinical protocol was described in detail  previously33. Briefly, 102 
subjects seeking dental treatment at the University clinic (University Cluj-Napoca) were included and treated 
between January 2012 and January 2014. Included patients were over 30 years old, had a minimum of 12 natu-
ral teeth in the oral cavity and clinical (at least two sites/quadrant with PD ≥ 6 mm) and radiographic signs of 
generalized severe chronic  periodontitis64 (generalized stages III–IV, grade B periodontitis)65, good level of oral 
hygiene [Full-mouth plaque-scores (FMPS) ≤ 25% prior to  SD66], systemically healthy. Subjects smoking at least 
10 cigarettes/day for the last 5 years were defined as  smokers67. Patients with systemic/local antibiotic therapy 
within the preceding 3 months, or any type of medication with a possible influence on the periodontium, preg-
nant/lactating patients or those who had non-surgical periodontal therapy within the previous 12 months were 
excluded. Informed written consent to participate in the study was obtained from all participants.
Medical history, clinical periodontal parameters (at 6 sites/tooth: PD, CAL), bleeding on probing (BOP) 
and  FMPS66 were recorded before and 3, 6 and 12 months after non-surgical periodontal therapy. Additionally, 
gingival crevicular fluid (GCF) and subgingival biofilm samples from the deepest pocket in each quadrant were 
taken at the same timepoints. All recordings, sampling and oral hygiene instructions were performed by one 
examiner (RJ) blinded to treatment allocation. SD (i.e. elimination of the subgingival calculus and biofilm) was 
performed within  24h63,68 was performed within 24 h at all sites with PD ≥ 4 mm by one experienced periodon-
tist (RC), blinded to group  allocation33,41. A computer-generated block-randomisation list divided the patients 
afterwards in three treatment groups:
Group A:  SD + placebo [placebo three times/day (TID) for 7 days].
Group B:  SD + systemic AMX + MET (both 500 mg 3TID for first 3 days, placebo 3TID for the rest 4 days).
Group C:  SD + systemic AMX + MET (both 500 mg 3TID for 7 days) (Fig. 1).
Patient allocation was performed after SD by another clinician (RT) [for details regarding the bottle pills 
please  see33].
At the follow-up appointments (3, 6, 12 months), the above mentioned parameters were recorded and only 
supragingival calculus was removed. Any residual periodontal pockets (pockets with PD = 4 mm + BOP, or 
PD ≤ 5 mm) were not re-instrumented.
GCF and microbial sampling and analysis. In each quadrant, the site with the deepest PD was selected 
for GCF and microbial sampling. After isolation with cotton rolls and careful removal of supragingival plaque 
with cotton pellets, a standard paper-strip (Periopaper, Oraflow, USA) was placed at the entrance of the peri-
odontal pocket for 30 s. After removal of the paper strip, a sterile paper-point was inserted for 30 s into the 
gingival crevice until mild resistance was felt. The four paper strips and four paper points obtained at one time-
point were each pooled into a sterile empty transportation container. GCF-samples were stored at − 70 °C and 
microbial samples at − 20 °C until assayed.
The host-derived biomarkers IL-1β, IL-10, IL-8 and MMP-8 were determined by commercially available 
ELISA-kits (R&D Systems Europe Ltd., Abingdon, UK) according to the manufacturer’s instruction. The detec-
tion levels of 2 pg/sample for IL-1β, IL-10 and IL-8 and 0.1 ng/sample for MMP-8. Samples were eluted over night 
at 4 °C into 750bµl phosphate-buffered saline (PBS, SigmaAldrich, St. Louis, MO, USA) and then centrifuged at 
400 g for 2 min. For ELISA, 100 µl aliquots of the supernatant were removed and used. The detection levels of 
the used test kits were 5 pg/sample (IL1β, IL-8, IL-10, MMP-8)69.
Real-time polymerase-chain-reaction (rtPCR) was used to detect the periodontal pathogens A. actinomycet-
emcomitans, P. gingivalis, Tannerella forsythia, Treponema denticola, Parvimonas micra, Fusobacterium nucleatum, 
Campylobacter rectus and Filifactor allocis. Bacterial DNA was extracted with Chelex 100 (Bio Rad Laboratories, 
Inc., Berkeley, CA, USA) and rt PCR was carried out (ABI 7500 rtPCR System, Applied Biosystems, Foster City, 
CA, USA). rtPCR amplifications were carried out using a 25 µl reaction volume [2.5 µl DNA template and 22.5 µl 
substrate mixture: 1.25 µl of each primer, 12.5 µl GoTaq qPCR Master Mix, 2 × Promega Corporation (Madison, 
WI, USA), 5 µl nucleic acid free  H2O]. Each batch of specimens contained negative  (H2O) and positive controls 
(2.5 µl genomic DNA of the respective reference strains in different concentrations). The cycling steps consisted 
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of an initial denaturation step at 95 °C for 2 min, 45 cycles at 95 °C for 15 s and at 60 °C for 60 s. The specificity 
of the amplification was assayed using melting curves and the detection level was 100 bacteria/sample69.
Statistical analyses. Statistical analyses were performed by an experienced professional statistician (CH) 
using the statistical software program (SPSS statistics 21, IBM, NY, USA). The present study was initially designed 
to find a difference between the control and the test groups for clinical parameters as the primary  outcome33,41. 
Shortly, the statistical unit was the patient and the primary outcome variable of the study was the difference in 
the number of sites per patient with PD ≥ 6 mm calculated between baseline and 12  months41. The power of the 
study was calculated for a difference of at least 5 sites with a PD ≥ 6 mm (standard deviation of 6 sites) between 
Figure 1.  Flowchart of the study. Included subjects were instructed for adequate oral hygiene and nonsurgically 
treated (SD: subgingival debridement). Immediately after SD, patients were randomised to medication (AMX-
amoxicillin, MET-metronidazole, TID-times per day). Patients were reevaluated at 3, 6 and 12 months when 
clinical periodontal parameters, microbiological and immunological outcomes were determined. Appropriate 
subject numbers at the follow-ups are given. The final number of subjects included in the per-protocol analysis 
(PP-analysis) is provided.
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both AB and placebo groups. A study power of 92% for a statistical significance level of 0.05 was achieved for 30 
subjects/ group; considering an attrition of 13%, 34 subjects/group were initially included.
For the clinical variables, intra-group clinical comparisons between the follow-ups were analysed by means 
of paired t-Test and Wilcoxon Signed Ranks Test. Comparisons between the groups at the various timepoints 
were performed adjusting for baseline values and smoking using ANCOVA and Bonferroni corrections.
Quantitative analysis of the microorganisms and inflammatory markers were first checked for normal dis-
tribution using Kolmogorov Smirnov test. Depending on these results, intra-group comparisons between the 
various timepoints were performed by means of paired t-Test and Wilcoxon Signed Ranks Test. For qualita-
tive changes of the immunomarkers, the Chi-square test was used, while for microbial changes McNemar Test 
was implemented. Inter-group comparisons were performed by means of ANCOVA, Mann–Whitney U and 
Kruskal–Wallis tests. Frequencies/number of patients positive for the microorganisms and immunomarkers 
were determined and intragroup comparisons were performed using McNemar test.
The residual number of sites with PD ≥ 6 mm as well as the number of sites reaching the clinical endpoint 
of pocket closure (< 4 mm) at 12 months were specifically determined for patients being positive/negative at 
baseline or at 6- and 12 months for the pathogens A. actinomycetemcomitans, P. gingivalis and T. denticola; group 
comparisons were performed using ANCOVA.
Finally, a Poisson regression analyses was conducted to determine the influence of the 3- or 7-day antimi-
crobial (AB) protocol, gender, smoking, BOP and FMPS at baseline and 12 months, initial mean PD and CAL, 
disease severity (≥ 10 sites with PD ≥ 6 mm), detection of A. actinomycetemcomitans, P. gingivalis, T. denticola, 
F. allocis and IL-1β at baseline on the residual number of deep sites (PD ≥ 6 mm) at 12 months.
Data availability
Study protocol data are available https ://www.isrct n.com/ISRCT N1760 5083. Data results are available from 
ralucacosgrea@gmail.com.
code availability
The study has been registered in the ISRCTN registry (registration date 16.06.2015, registration number: study 
ID ISRCTN17605083) and is available on the website http://www.isrct n.com/ISRCT N1760 5083.
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